News | July 18, 2022
Glaucoma Research Foundation launches catalyst for a to prevent and cure neurodegeneration
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
TruPharma has commenced commercial marketing of Sage's approved generic cartridge product
It is used to control, prevent and normalize the symptoms associated with Alzheimer's disease, attention disorder, bipolar disorder, Parkinson's disease among others
Parkinson's disease treatment is the first and only carbidopa/levodopa (CD/LD) tablet designed to be divided for precise dosing
It is a novel oral NLRP3 inflammasome inhibitor
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Droxidopa capsules, 100 mg, 200 mg, and 300 mg is a generic equivalent of Northera capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA
Subscribe To Our Newsletter & Stay Updated
